Prime Medicine Prices $125M Underwritten Stock Offering at $4.30 Reference
PRME sits 42% above its 52-week low of $2.67.
Summary
Prime Medicine is raising $125 million (up to $143.75 million with the greenshoe) in an underwritten common stock offering, with the price still blank and a $4.30 November 9 close as the reference. The cash buys runway for Wilson disease and AATD programs at meaningful dilution to existing holders.
Key Events · Financing and Capital Events · PRME
-
$125M Underwritten Offering Launched
Prime Medicine is offering $125,000,000 of common stock, with a 30-day underwriter option for up to $18,750,000 of additional shares. The public offering price is left blank in this preliminary prospectus supplement.
-
Pricing Reference Set at $4.30
The filing cites a November 9, 2026 closing price of $4.30 per share as the reference; the actual deal price and discount are not yet stated. At $4.30, the base deal equals about 29.1 million shares ($125M / $4.30) against 180,737,548 shares outstanding as of June 30, 2026 — roughly 16% more shares.
-
Cash Position Down to $61.2M
Preliminary September 30, 2026 cash, cash equivalents and short-term investments were about $61.2 million, excluding $13.7 million of restricted cash, versus $95.1 million at June 30, 2026. The figures are unaudited and not reviewed by PricewaterhouseCoopers.
-
Proceeds Fund Wilson and AATD Programs
Net proceeds are earmarked primarily for the Wilson disease and AATD programs and other R&D, with the remainder for working capital, capital expenditures and general corporate purposes.
Analysis · PRME · Life Sciences
Prime Medicine is selling $125 million of common stock in an underwritten deal, with a 30-day option for up to $18.75 million more. The filing sets the reference price at $4.30 (the November 9 close) but leaves the actual public offering price blank, so the final discount is not yet known. This raise is survival capital: cash stood at roughly $61.2 million at September 30, down from $95.1 million at June 30, and the company has previously disclosed a going-concern warning. Proceeds go mainly to the Wilson disease and AATD programs. At the $4.30 reference, the base deal is about 29.1 million shares against 180.7 million outstanding — roughly 16% more shares — and the greenshoe would add about 4.4 million more.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRME was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $707.4M. The 52-week trading range was $2.67 to $5.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.